Radiomer Therapeutics

Radiomer Therapeutics is an early-stage biotech pioneering a novel class of targeted radiopharmaceuticals using its Raptamer platform. Raptamers combine the high affinity of antibodies with favorable pharmacokinetics for radiopharmaceutical delivery, enabling rapid development from target identification to clinical entry. The company is on track to initiate its first Phase 0 imaging/dosimetry trial in cancer patients by early 2025, with a pipeline focused on oncology. Backed by Fannin and led by a seasoned management team with extensive drug development experience, Radiomer is positioning itself in the rapidly expanding radiopharmaceutical therapeutics market.

Raptamer platform: peptide-oligonucleotide hybrid targeting vectors for radiopharmaceuticals. Combines ssDNA backbone with peptide-like side chains for high affinity and specificity. Designed for modular payload attachment, favorable pharmacokinetics, good tissue penetration, and stable manufacturing.

Radiomer competes in the targeted radiopharmaceutical space against leaders like Novartis (Pluvicto, Lutathera) and Bayer (Xofigo), as well as numerous biotechs (e.g., RayzeBio, Fusion Pharmaceuticals, Aktis Oncology). Competition is based on targeting novel antigens, improving therapeutic indices, and developing new radioisotope conjugates.